Literature DB >> 11856081

Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease.

O Dewit1, R Vanheuverzwyn, J P Desager, Y Horsmans.   

Abstract

BACKGROUND: The inhibition of thiopurine methyltransferase activity, one of the enzymes responsible for azathioprine metabolism, by aminosalicylates has been described in an in vitro study. This could result in a higher risk of bone marrow depression when using the two drugs together. AIM: To investigate the in vivo interaction between azathioprine and aminosalicylates in quiescent Crohn's disease by measuring 6-thioguanine nucleotide levels, thiopurine methyltransferase activity and the plasma levels of the acetylated metabolite of 5-aminosalicylic acid.
METHODS: Sixteen patients taking a stable dose of azathioprine, plus sulfasalazine or mesalazine, were enrolled and completed the study. They were not taking any drugs interfering with azathioprine metabolism. Four visits every 4 weeks were held over a 3-month period. Aminosalicylate administration was withdrawn after the second visit. At each visit, the blood cell count, inflammatory parameters, levels of 6-thioguanine nucleotide and the acetylated metabolite of 5-aminosalicylic acid and thiopurine methyltransferase activity were determined.
RESULTS: After aminosalicylate withdrawal, mean 6-thioguanine nucleotide levels decreased significantly from 148 pmol (57-357 pmol) to 132 pmol (56-247 pmol) per 8 x 10(8) red blood cells (P=0.027), without significant changes in thiopurine methyltransferase activity or biological parameters.
CONCLUSIONS: This in vivo study favours the existence of an interaction between azathioprine and aminosalicylates through a mechanism which remains unclear. This drug-drug interaction should be taken into account when using azathioprine and aminosalicylates simultaneously.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856081     DOI: 10.1046/j.1365-2036.2002.01156.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  21 in total

1.  Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

Authors:  Gabriele Stocco; Eva Cuzzoni; Sara De Iudicibus; Diego Favretto; Noelia Malusà; Stefano Martelossi; Elena Pozzi; Paolo Lionetti; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Severe myalgia associated with mesalazine treatment in a child with Crohn's disease.

Authors:  Mladen Persić; Goran Palcevski; Irena Slavić; Vera Vlahović-Palcevski
Journal:  Eur J Clin Pharmacol       Date:  2007-01-23       Impact factor: 2.953

3.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

4.  Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.

Authors:  P de Graaf; N K H de Boer; D R Wong; S Karner; B Jharap; P M Hooymans; A I Veldkamp; C J J Mulder; A A van Bodegraven; M Schwab
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 5.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 6.  Use of thiopurines in inflammatory bowel disease: Safety issues.

Authors:  Anastasia Konidari; Wael El Matary
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

7.  Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.

Authors:  Margalida Calafat; Míriam Mañosa; Fiorella Cañete; Eugeni Domènech
Journal:  Drugs Aging       Date:  2021-01-13       Impact factor: 3.923

Review 8.  Optimising use of thiopurines in inflammatory bowel disease.

Authors:  Lawrence Sunder Raj; A Barney Hawthorne
Journal:  Frontline Gastroenterol       Date:  2010-04-01

9.  Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies.

Authors:  Fernando Bermejo; Javier P Gisbert
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

10.  Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine.

Authors:  Daniel B Zandman; Mark A Peppercorn
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.